|

Imatinib Clinical Trials

12 actively recruiting trials across 6 locations

No change since May 2026

Also known as: Gleevec, Glivec, Imatinib Mesylate, Imatinib mesylate, STI571 +1 more

Pipeline

Phase 1: 3Phase 2: 6Phase 3: 1Phase 4: 2

Top Sponsors

  • National Cancer Institute (NCI)2
  • Wei Zhao1
  • University of California, San Francisco1
  • University of California, San Diego1
  • Reema A. Patel1

Indications

  • Cancer12
  • Gastrointestinal Stromal Tumors2
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive1
  • Familial Platelet Disorder With Predisposition to Myeloid Malignancies1
  • Hematological Neoplasms1

Other5 trials

A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Phase 3
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Phase 4
Imatinib and Trametinib for KRAS-mutated Solid Tumor
Phase 1
Precision Cancer Therapy in Rare Cancers
Phase 2
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
Phase 2

La Jolla, California2 trials

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

UC San Diego Moores Cancer Center

Phase 2
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

University of California, San Diego

Phase 1

Birmingham, Alabama1 trial

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 2

Lexington, Kentucky1 trial

Imatinib TDM in GIST

Markey Cancer Center

Phase 2

Bethesda, Maryland1 trial

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

National Institutes of Health Clinical Center

Phase 1

Ann Arbor, Michigan1 trial

Asciminib Roll-over Study

Michigan Med University of Michigan

Phase 4

Detroit, Michigan1 trial

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

The Barbara Ann Karmanos Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.